Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 3937 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 


 
ORIGINAL ARTICLE Table of Contents   
Year : 2019  |  Volume : 30  |  Issue : 3  |  Page : 606-614
The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis


1 UCL Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK; Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Zagazig University, Zagazig, Egypt
2 UCL Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK
3 Division of Infection and Immunity, Center for Virology, Royal Free NHS Trust and UCL Medical School, London, UK

Correspondence Address:
Ali M Shendi
Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Zagazig University, 44519 Zagazig

Login to access the Email id


DOI: 10.4103/1319-2442.261333

PMID: 31249224

Rights and Permissions

Cytomegalovirus (CMV) is one of opportunistic infections post solid organ transplant and remains a cause of morbidity and mortality. Mammalian target of rapamycin inhibitors has a theoretical antiviral advantage compared to conventional immunosuppression. The primary outcome was to assess the viremic response and kidney function in a cohort of kidney transplant recipients (KTRs) with difficult to manage CMV infection when converted to sirolimus. We retrospectively analyzed the outcome of substituting sirolimus for mycophenolate mofetil (MMF) or tacrolimus in 18 KTR with difficult to manage, resistant/recurrent CMV viremia unresponsive or intolerant of standard anti-CMV treatment, or immunosuppression reduction. Safety and feasibility of sirolimus conversion were assessed through studying CMV viral loads, creatinine levels, immunosuppression, antiviral therapy, kidney function, and acute rejection episodes before and after starting sirolimus as well as the sirolimus side effects. Data were collected from the hospital filing system. The Wilcoxon matched-pairs signed-rank test and Friedman test were used for statistical analysis. The area under the curve for Log10 CMV viral load (log10 copies/ml) was significantly higher before than after the sirolimus switch (P = 0.0156). The median number of days on antiviral treatment was reduced after conversion to sirolimus [48 days (0–95); vs. 68 days (21–146)]. Acute rejection occurred more commonly before than after starting sirolimus [n =5 (27.7%) vs. n = 2 (11.1%)]. Median serum creatinine before conversion to sirolimus was 175.5 μmol/L (79–243), and showed no deterioration three months and one year after conversion [148 (69–271) and 162.5 (69–287) μmol/L, respectively, P = 0.002]. The use of sirolimus, often alongside tacrolimus and after discontinuation of MMF, is a useful strategy in treating recurrent CMV viremia without provoking rejection.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed378    
    Printed2    
    Emailed0    
    PDF Downloaded100    
    Comments [Add]    

Recommend this journal